Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212366 | 1.00 | CACNA2D1 (0.55) | CACNA2D1OPRM1 | |
| SCHEMBL23212362 | 1.00 | CACNA2D1 (0.55) | CACNA2D1OPRM1 | |
| SCHEMBL23212364 | 1.00 | CACNA2D1 (0.55) | CACNA2D1OPRM1 | |
| SCHEMBL23212446 | 1.00 | CACNA2D1 (0.55) | CACNA2D1OPRM1 | |
| SCHEMBL24172915 | 0.93 | CACNA2D1 (0.64) | CACNA2D1OPRM1 | |
| SCHEMBL23212292 | 0.90 | CACNA2D1 (0.69) | CACNA2D1OPRM1 | |
| SCHEMBL23212287 | 0.90 | CACNA2D1 (0.69) | CACNA2D1OPRM1 | |
| SCHEMBL23212289 | 0.90 | CACNA2D1 (0.69) | CACNA2D1OPRM1 | |
| SCHEMBL23212649 | 0.90 | CACNA2D1 (0.69) | CACNA2D1OPRM1 | |
| SCHEMBL23212650 | 0.90 | CACNA2D1 (0.69) | CACNA2D1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479830-B2 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2025-11-25 | — | — | US | disclosed |
| US-20220380345-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-12-01 | — | — | US | disclosed |
| CN-114502549-A | Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain | 埃斯特韦制药股份公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021069339-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479830-B2 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | CACNA2D1 90/4885OPRM1 4/4885 |
| US-20220380345-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | CACNA2D1 90/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.